Below you can find the list of 10 largest generic drug companies. For a detailed coverage of this topic and a more comprehensive list, please see the 21 largest generic drug companies.
Endo is an American generic and specialty medicine company that derives its major sales revenue from the US healthcare system.
9. Stada
Revenue – $2,922 million
Number Of Employees – 10,416
Market Cap –0.432B
TTM $- 1,530.25 million
Germany based company, STADA, specializes in the production of generic and over-the-counter drugs. The company recently signed an exclusive supply agreement with cannabis company MediPharm Labs under which it will distribute medical cannabis products in Germany, and also provide manufacturing, logistics, and regulatory support.
Monkey Business Images/Shutterstock.com
8. Aurobindo Pharma
Revenue – $3,082.45million
Number Of Employees – 18,469
Market Cap –7.0552B
TTM $- 3,263.84 million
The company is an Indian pharmaceutical involved in manufacturing of generics drugs and APIs. The company recently bagged the approval of the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride in 0.9% sodium chloride injections, a generic version of Hospira’s Precedex.
7. Mallinckrodt
Revenue – $3,162.50million
Number Of Employees – 3,400
Market Cap –15.313M
TTM $- 3,192.50 million
Mallinckrodt is a American-Irish domiciled maker of specialty pharmaceuticals, generic drugs and imaging agents. The company ran into significant issues over the course of the past year, including a bankruptcy being filed against it.
racorn/Shutterstock.com
6. Sun Pharmaceuticals
Revenue – $4,451 million
Number Of Employees – 36,000
Market Cap –18.53 B
TTM $- 4,413million
Indian companies are big on our list, and Sun pharmaceuticals in by far the largest generic drug company in the Indian market and appears in our list of the largest generic drug companies in the world. The company came into existence in the 80s and has gone through several acquisitions and joint ventures to solidify its position in the drugs market.
5. Fresenius
Revenue – $8,380 million
Number Of Employees – 39,627
Market Cap –N/A
TTM $-N/A
While Fresenius is a well-known German company in the pharma and life sciences domain, the company plans to keep strengthening its generic drugs portfolio and business segment through. It has two major acquisitions in plans, one being Akorn, a developer and manufacturer of generic drugs, and secondly the biosimilars segment of Merck KGaA.
wavebreakmedia/Shutterstock.com
4. Sandoz
Revenue – $9,700 million
Number Of Employees – 33,000
Market Cap –N/A
TTM $-N/A
Sandoz is the generic segment of pharma giant Novartis. The segment especially ran into trouble in the past for concerns over pricing of generic drugs dating back to 2011. Novartis is in the process of evaluating these allegations against the division. Sandoz also plans to expand its operations in Japan by acquiring Aspen Pharmacare’s generics business in Japan.
Netherlands global generic giant Mylan has always been one of the strong players in the market. However, as pointed earlier, the company is now part of Pfizer and recently in November 2020, Mylan merged with Pfizer’s generic medicine division Upjohn as spin-off company Viatris was formed.
Definitely one of the market leaders exclusively involved in the generics segment, Teva, produces and markets high quality generics and specialty drugs. The company acquired Allergan’s (NYSE: AGN) generic division in 2015 in a $40.5 billion deal to strengthen its market position.
While Teva has always been considered a leader of the market niche, Pfizer has slowly made its presence in the generics market to top the list of the 21 largest generic drug companies, mainly through strategic acquisitions. Major acquisitions include the buyout of Hospira and more recently the merger with Mylan. Pfizer has steadily built a strong segment of generics in its products, through expertise from the well established segments of these companies.
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.
Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.
At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.
Do the math. According to Musk, this technology could be worth $250 trillion by 2040.
Put another way, that’s roughly equal to:
175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias
And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.
It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.
Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.
How could anything be worth that much?
The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.
And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.
What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.
In fact, Verge argues this company’s supercheap AI technology should concern rivals.
Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.
Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.
When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.
Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…
But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.
And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…
This prediction might not be bold at all:
A few years from now, you’ll wish you’d owned this stock.
The best part? You can discover everything about this company and its groundbreaking technology right now.
I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.
Trust me — you’ll want to read this report before putting another dollar into any tech stock.
For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!
Here’s why this is a deal you can’t afford to pass up:
• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
• Bonus Reports: Premium access to members-only fund manager video interviews
• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.
If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.
Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.
Here’s what to do next:
1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.
2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.
Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!
